Home >> Oncology/Hematology >> Oncology/Hematology >> Baked Goods >> Technology & Media >>

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 81 | Code: MRS - 18275

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015’, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Basal Cell Carcinoma (Basal Cell Epithelioma) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Basal Cell Carcinoma (Basal Cell Epithelioma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Basal Cell Carcinoma (Basal Cell Epithelioma) Overview 8
Therapeutics Development 9
Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview 9
Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Comparative Analysis 10
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Development by Companies 11
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Investigation by Universities/Institutes 12
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Development by Companies 16
Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Investigation by Universities/Institutes 17
Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development 18
4SC AG 18
Biofrontera AG 19
Biogenomics Limited 20
Biosceptre International Limited 21
Bristol-Myers Squibb Company 22
Genextra S.p.a. 23
MediGene AG 24
Novartis AG 25
Oncovir, Inc. 26
Redx Pharma Ltd 27
Transgene SA 28
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
aminolevulinic acid hydrochloride - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BIL-010t - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BMS-833923 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CIGB-128 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
CS-S/BCC-1 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CS-TATI-1 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
DAC-060 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
erismodegib - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
interferon alfa-2b (recombinant) - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
LEQ-506 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Oshadi D + Oshadi R - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Poly-ICLC - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
sinecatechins - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecule to Inhibit Smoothened Receptor for Basal Cell Carcinoma - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecules to Inhibit Casein Kinase 1 for Cancer - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
TG-1042 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Basal Cell Carcinoma (Basal Cell Epithelioma) - Recent Pipeline Updates 62
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects 71
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products 72
Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones 73
Featured News & Press Releases 73
Mar 02, 2015: Basal Cell Carcinoma Drug Encourages Both Cancer Regression and Loss of Taste in Patients 73
Sep 17, 2014: Novartis presents oncology research advances with new data on sonidegib at ESMO 2014 73
Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma 74
Jun 01, 2014: Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma 74
May 23, 2014: Curis Announces Abstracts for Its Partnered Programs, Erivedge to be Presented at the 2014 ASCO Annual Meeting 75
Feb 19, 2014: Novartis investigational compound LDE225 met primary endpoint in pivotal trial for patients with advanced basal cell carcinoma 76
Jul 15, 2013: Roche’s Erivedge receives conditional EU approval for treatment of advanced basal cell carcinoma 77
Jun 11, 2013: Roche's Erivedge Gets Swiss Approval For Treatment Of Basal Cell Carcinoma 78
May 16, 2013: Curis Announces Presentation Of Erivedge Clinical Results At ASCO Annual Meeting 78
May 10, 2013: Curis Obtains Australian Approval For Erivedge For Treatment Of Adult Patients With Metastatic Basal Cell Carcinoma 78
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 80
Disclaimer 81

List of Tables
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2015 9
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by 4SC AG, H1 2015 18
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biofrontera AG, H1 2015 19
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biogenomics Limited, H1 2015 20
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biosceptre International Limited, H1 2015 21
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Bristol-Myers Squibb Company, H1 2015 22
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Genextra S.p.a., H1 2015 23
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by MediGene AG, H1 2015 24
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Novartis AG, H1 2015 25
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Oncovir, Inc., H1 2015 26
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Redx Pharma Ltd, H1 2015 27
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Transgene SA, H1 2015 28
Assessment by Monotherapy Products, H1 2015 29
Assessment by Combination Products, H1 2015 30
Number of Products by Stage and Target, H1 2015 32
Number of Products by Stage and Mechanism of Action, H1 2015 34
Number of Products by Stage and Route of Administration, H1 2015 36
Number of Products by Stage and Molecule Type, H1 2015 38
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics - Recent Pipeline Updates, H1 2015 62
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H1 2015 71
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, H1 2015 72

List of Figures
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2015 9
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Products, H1 2015 15
Assessment by Monotherapy Products, H1 2015 29
Number of Products by Top 10 Targets, H1 2015 31
Number of Products by Stage and Top 10 Targets, H1 2015 31
Number of Products by Top 10 Mechanism of Actions, H1 2015 33
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34
Number of Products by Top 10 Routes of Administration, H1 2015 35
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 35
Number of Products by Top 10 Molecule Types, H1 2015 37
Number of Products by Stage and Top 10 Molecule Types, H1 2015 38

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing